Vl. Șandor *, M. A. Birț **, M. Follidis ***
* Conf. Dr. VI. ȘANDOR, Catedra de Farmacologie, U.M.F. “Iuliu Hațieganu” Cluj-Napoca
** Conf. asoc. Dr. M. A. BIRȚ, Fac. Psihologie, Univ. “Babeș-Bolyoi” Cluj-Napoca, Medic șef secție Psihiatrie, Spitalul Clinic de Adulți Cluj-Napoca
*** Farm. Dr. M. FOLLIDIS, U.C.B. Grecia
Abstract
Piracetam , a prototype of the nootropic drugs, influences mainly the cognitive processes at the level of telencephalon . It interferes in a modulating way the neurotransmission, the biosynthesis of the phospholipids which ensure the cellular integrity and plasticity of the neurons, erythrocytes, platelets and epithelial cells. It increases the neuronal resistence against hypoxia, it reduces the blood viscosity and it has antispastic effects. The outstanding pharmacokinetic characteristics of piracetam, as well as its extremely low toxicity, offers safety in its administration. Obvious favourable effects in the treatment of myoclonus, of vertigo, of sickle cell anemia and of the Raynaud syndrome were observed. It improves the evolution of the acute ischaemic stroke and of subsequent aphasia. It influences partially the cognitive processes in aged persons, in dementia and in posthypoxiccerebra sequelae. The effects are modest in dyslexia. In all these situations, piracetam is chronically administered , in high doses, associated to the basic treatment recommended for all these diseases.